The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)

Table of contents


Chemical Compound Review

AC1NSXLQ     magnesium(2S)-2-[[(2S,3R)-4- [2-[(1R)-1...

This record was replaced with 5319055.
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of (2R)-2-[3-[(2S,3S)-3-[(1S)-1-carboxy-2-(3,4-dihydroxyphenyl)ethoxy]carbonyl-2-(3,4-dihydroxyphenyl)-7-hydroxy-2,3-dihydrobenzofuran-4-yl]propanoyloxy]-3-(3,4-dihydroxyphenyl)propanoic acid


High impact information on (2R)-2-[3-[(2S,3S)-3-[(1S)-1-carboxy-2-(3,4-dihydroxyphenyl)ethoxy]carbonyl-2-(3,4-dihydroxyphenyl)-7-hydroxy-2,3-dihydrobenzofuran-4-yl]propanoyloxy]-3-(3,4-dihydroxyphenyl)propanoic acid


Chemical compound and disease context of (2R)-2-[3-[(2S,3S)-3-[(1S)-1-carboxy-2-(3,4-dihydroxyphenyl)ethoxy]carbonyl-2-(3,4-dihydroxyphenyl)-7-hydroxy-2,3-dihydrobenzofuran-4-yl]propanoyloxy]-3-(3,4-dihydroxyphenyl)propanoic acid


Biological context of (2R)-2-[3-[(2S,3S)-3-[(1S)-1-carboxy-2-(3,4-dihydroxyphenyl)ethoxy]carbonyl-2-(3,4-dihydroxyphenyl)-7-hydroxy-2,3-dihydrobenzofuran-4-yl]propanoyloxy]-3-(3,4-dihydroxyphenyl)propanoic acid


Anatomical context of (2R)-2-[3-[(2S,3S)-3-[(1S)-1-carboxy-2-(3,4-dihydroxyphenyl)ethoxy]carbonyl-2-(3,4-dihydroxyphenyl)-7-hydroxy-2,3-dihydrobenzofuran-4-yl]propanoyloxy]-3-(3,4-dihydroxyphenyl)propanoic acid


Associations of (2R)-2-[3-[(2S,3S)-3-[(1S)-1-carboxy-2-(3,4-dihydroxyphenyl)ethoxy]carbonyl-2-(3,4-dihydroxyphenyl)-7-hydroxy-2,3-dihydrobenzofuran-4-yl]propanoyloxy]-3-(3,4-dihydroxyphenyl)propanoic acid with other chemical compounds


Gene context of (2R)-2-[3-[(2S,3S)-3-[(1S)-1-carboxy-2-(3,4-dihydroxyphenyl)ethoxy]carbonyl-2-(3,4-dihydroxyphenyl)-7-hydroxy-2,3-dihydrobenzofuran-4-yl]propanoyloxy]-3-(3,4-dihydroxyphenyl)propanoic acid

  • In contrast, rats given magnesium lithospermate B (10 mg/kg body weight) orally for 30 days after subtotal nephrectomy showed restoration of SOD and catalase activities to almost normal levels [1].
  • The activity of kallikrein in urine increased markedly and significantly in rats given 5 or 10 mg of magnesium lithospermate B for 12 or 24 days [10].

Analytical, diagnostic and therapeutic context of (2R)-2-[3-[(2S,3S)-3-[(1S)-1-carboxy-2-(3,4-dihydroxyphenyl)ethoxy]carbonyl-2-(3,4-dihydroxyphenyl)-7-hydroxy-2,3-dihydrobenzofuran-4-yl]propanoyloxy]-3-(3,4-dihydroxyphenyl)propanoic acid


  1. Magnesium lithospermate B suppresses the increase of active oxygen in rats after subtotal nephrectomy. Yokozawa, T., Dong, E., Oura, H., Kashiwagi, H., Nonaka, G., Nishioka, I. Nephron (1997) [Pubmed]
  2. Potentiating effect of converting enzyme inhibitor captopril to the renal responses of magnesium lithospermate B in rats with adenine-induced renal failure. Yokozawa, T., Chung, H.Y., Lee, T.W., Oura, H., Nonaka, G., Nishioka, I. Chem. Pharm. Bull. (1991) [Pubmed]
  3. Effect of magnesium lithospermate B in rats with sodium-induced hypertension and renal failure. Yokozawa, T., Lee, T.W., Oura, H., Nonaka, G., Nishioka, I. Nephron (1992) [Pubmed]
  4. Effect of magnesium lithospermate B on calcium and nitric oxide in endothelial cells upon hypoxia/reoxygenation. Luo, W.B., Dong, L., Wang, Y.P. Acta Pharmacol. Sin. (2002) [Pubmed]
  5. A novel Na+ channel agonist, dimethyl lithospermate B, slows Na+ current inactivation and increases action potential duration in isolated rat ventricular myocytes. Yoon, J.Y., Ahn, S.H., Oh, H., Kim, Y.S., Ryu, S.Y., Ho, W.K., Lee, S.H. Br. J. Pharmacol. (2004) [Pubmed]
  6. Extremely low bioavailability of magnesium lithospermate B, an active component from Salvia miltiorrhiza, in rat. Zhang, Y., Akao, T., Nakamura, N., Duan, C.L., Hattori, M., Yang, X.W., Liu, J.X. Planta Med. (2004) [Pubmed]
  7. Simultaneous determination of magnesium lithospermate B, rosmarinic acid, and lithospermic acid in beagle dog serum by liquid chromatography/tandem mass spectrometry. Li, X., Yu, C., Sun, W., Liu, G., Jia, J., Wang, Y. Rapid Commun. Mass Spectrom. (2004) [Pubmed]
  8. Selective modulation of L-type calcium current by magnesium lithospermate B in guinea-pig ventricular myocytes. Wang, W., Hu, G.Y., Wang, Y.P. Life Sci. (2006) [Pubmed]
  9. Peroxynitrite scavenging activity of lithospermate B from Salvia miltiorrhiza. Soung, d.o. .Y., Rhee, S.H., Kim, J.S., Lee, J.Y., Yang, H.S., Choi, J.S., Yokozawa, T., Han, Y.N., Chung, H.Y. J. Pharm. Pharmacol. (2003) [Pubmed]
  10. Augmentation of renal response by magnesium lithospermate B. Yokozawa, T., Oura, H., Lee, T.W., Nonaka, G., Nishioka, I. Nephron (1991) [Pubmed]
  11. Contribution of prostaglandins to the renal responses to magnesium lithospermate B isolated from salviae miltiorrhizae radix. Yokozawa, T., Chung, H.Y., Lee, T.W., Oura, H., Tanaka, T., Nonaka, G., Nishioka, I., Hirai, A. Chem. Pharm. Bull. (1989) [Pubmed]
  12. Magnesium lithospermate B ameliorates cephaloridine-induced renal injury. Yokozawa, T., Dong, E., Liu, Z.W., Shibata, T., Hasegawa, M., Watanabe, H., Oura, H. Experimental and toxicologic pathology : official journal of the Gesellschaft für Toxikologische Pathologie. (1997) [Pubmed]
  13. Effects of a Dan Shen component, magnesium lithospermate B, in nephrectomized rats. Yokozawa, T., Zhou, J.J., Hattori, M., Inaba, S., Okada, T., Oura, H., Nonaka, G., Nishioka, I. Nippon Jinzo Gakkai shi. (1995) [Pubmed]
  14. Pharmacokinetics of magnesium lithospermate B after intravenous administration in beagle dogs. Li, X.C., Yu, C., Sun, W.K., Liu, G.Y., Jia, J.Y., Wang, Y.P. Acta Pharmacol. Sin. (2004) [Pubmed]
  15. Free radical scavenging and inhibition of lipid peroxidation by magnesium lithospermate B. Wu, X.J., Wang, Y.P., Wang, W., Sun, W.K., Xu, Y.M., Xuan, L.J. Acta Pharmacol. Sin. (2000) [Pubmed]
  16. Effective isolation of magnesium lithospermate B and its inhibition of aldose reductase and fibronectin on mesangial cell line. Jung, M., Lee, H.C., Ahn, C.W., Park, W., Choi, S., Kim, H., Cho, D., Lee, G.T., Li, H.R. Chem. Pharm. Bull. (2002) [Pubmed]
  17. Confirmation that magnesium lithospermate B ameliorates paraquat-induced injury in cultured renal epithelial cells. Yokozawa, T., Oura, H., Nishioka, I. Nephron (1998) [Pubmed]
  18. Magnesium lithospermate B inhibits hypoxia-induced calcium influx and nitric oxide release in endothelial cells. Luo, W.B., Wang, Y.P. Acta Pharmacol. Sin. (2001) [Pubmed]
  19. The promoting action of magnesium lithospermate B on the kinin-prostaglandin E2 system in the kidney. Chung, H.Y., Kim, J.S., Chung, H.Y., Yokozawa, T., Oura, H. Pharmacol. Toxicol. (1995) [Pubmed]
  20. Magnesium lithospermate B improves renal function via the kallikrein-prostaglandin system in rats with renal failure. Yokozawa, T., Chung, H.Y., Lee, T.W., Oura, H., Nonaka, G., Nishioka, I. Nippon Jinzo Gakkai shi. (1990) [Pubmed]
WikiGenes - Universities